Drug Testing: Technologies and Global Markets
The global drug of abuse (DOA) testing market reached nearly $3.0 billion in 2016. This market is estimated to grow at a compound annual growth rate (CAGR) of 4.5% to reach nearly $3.9 billion by 2022 from $3.1 billion in 2017.
Urine DOA testing, the largest segment of the market, reached $1.7 billion in 2016. This market is estimated to grow at a CAGR of 4.5% to reach $2.2 billion by 2022 from $1.8 billion in 2017.
DOA testing sales by oral fluids, the fastest growing segment of the market, reached $198 million in 2016. This market is estimated to grow at a CAGR of 7.8% to reach $320 million by 2022 from $220 million in 2017.
Urine DOA testing, the largest segment of the market, reached $1.7 billion in 2016. This market is estimated to grow at a CAGR of 4.5% to reach $2.2 billion by 2022 from $1.8 billion in 2017.
DOA testing sales by oral fluids, the fastest growing segment of the market, reached $198 million in 2016. This market is estimated to grow at a CAGR of 7.8% to reach $320 million by 2022 from $220 million in 2017.
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing the Study
Intended Audience
Scope of Report
Methodology
Information Sources
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
Executive Summary
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Single- Vs. Multi-Parameter Test
DOA Screening
Confirmation Testing
Urine Tests
Other Testing Methods
Blood Testing
Oral Fluid Testing
Saliva Testing
Sweat Testing
Hair Testing
Testing Locations
Laboratory-Based DAT
Criminal Justice
Police
Prisons
Probation
Workplace Screening
Others
Military
Customs and Excise
Education
Point of Care DATS
Onsite Testing Vs Laboratory Testing
Sample Types for Laboratory Testing
Urine Testing
Hair Testing
Saliva/Oral Fluid Testing
Blood Testing
Sweat Testing
Eye Reflex
Detection Period
Fooling a Drug Test
Fooling Hair Testing
Fooling Saliva Testing
Sample Validity Tests
False Positives and False Negatives
False Positives
False Negatives
Drug Clearance and Testing Window
Testing Technologies
Immunoassays
Enzyme Immunoassay (EIA)
Enzyme-Linked Immunosorbent Assay (ELISA)
Enzyme Multiplied Immunoassay Technology (EMIT)
Fluorescence Polarization Immunoassay (FPIA)
Radioimmunoassay (RIA)
Chromatography
Gas Chromatography
High Performance Liquid Chromatography
Thin-Layer Chromatography
Mass Spectrometry
Capillary Electrophoresis
Hyphenated Mass Spectrometric/Chromatography
Gas Chromatography-Mass Spectrometry
Eye Reflex Measurements
CHAPTER 4 GOVERNMENT REGULATIONS: DRUG TRAFFICKING AND DRUG ABUSE TESTING
North America
Canada
Drug Free Workplace
Mexico
U.S.
Drug-Free Workplace
State Marijuana Legalization
U.S. Department of Transportation
Drug Testing in the Military
Drug Testing for Welfare Recipients and Public Assistance
History and Overview
Drug Testing for Individuals Convicted of Drug Felonies
2017 LEGISLATION
2016 LEGISLATION
Legislative Proposals
Legislative Enactments
2015 LEGISLATION
Legislative Proposals
Legislative Enactments
2014 LEGISLATION
Legislative Proposals
Legislative Enactments
2013 LEGISLATION
Legislative Proposals
Legislative Enactments
2012 LEGISLATION
South America
Bolivia
Brazil
Drug-Free Workplace
Colombia
Ecuador
Guyana
Paraguay
Peru
Central America and the Caribbean
Costa Rica
Cuba
El Salvador
Guatemala
Haiti
Jamaica
Nicaragua
Panama
Honduras
The Bahamas
The Netherlands Antilles
Trinidad and Tobago
Europe
Bosnia and Herzegovina
Denmark
France
Germany
Italy
Latvia
Norway
Romania
Sweden
Switzerland
The Netherlands
The United Kingdom
Asia-Pacific
Australia
Bangladesh
Bhutan
Cambodia
Hong Kong
India
The NDPS (Regulation of Controlled Substances) Order, 1993
Japan
Maldives
Myanmar
Nepal
New Zealand
Singapore
South Korea
Sri Lanka
Taiwan
Thailand
Vietnam
CHAPTER 5 OVERVIEW OF DRUG ABUSE TESTING
Drug Abuse Testing
International Drug Trafficking and Illicit Drug Use Trends by Drug Type
Amphetamine-Type Stimulants Market
Cannabis Market
Coca/Cocaine Market
Opium/Heroin Market
International Drug Trafficking and Illicit Drug Use Trends by Geographic Region
Africa
Central America and Caribbean
North America
South America
East and Southeast Asia
South Asia
West Asia
Europe
Oceania
U.S. DOA Statistics
National Household Survey on Drug Abuse: SAMHSA U.S.
CHAPTER 6 GLOBAL DRUGS OF ABUSE TESTING MARKET BY SAMPLE TYPE
DOA Testing Sales
Global Sales of DOA Testing by Urine
Global Sales of DOA Testing by Blood
Global Sales of DOA Testing by Oral Fluid
Global Sales of DOA Testing by Hair
Global Sales of DOA Testing by Sweat
Global Sales of DOA Testing by Other Sample Types
CHAPTER 7 GLOBAL INDUSTRY STRUCTURE
Regional Analysis
Total DOA Testing and Drug Monitoring Markets and Forecasts
Growth Trends-Laboratory-based and Onsite DOA Testing Markets
Laboratory-based DOA Testing Market and Forecast
Onsite DOA Testing Market and Forecast
Competitive Analysis
Key Market Players in the DOA Testing Markets and Their Products
Laboratory-based DOA Testing Market Segment
Onsite Testing Market Segment for DOA
Common DOA and Most Popular Devices Used for Testing Them
Companies in the Oral Fluid, Hair and Sweat Testing Segments for DOA
CHAPTER 8 PATENT ANALYSIS
CHAPTER 9 COMPANY PROFILES
1 STEP DETECT ASSOCIATES
ABBOTT DIAGNOSTICS
ACCUTECH
ACON LABORATORIES
AGILENT TECHNOLOGIES
ALERE
ALFA SCIENTIFIC
AMERICAN BIO MEDICA
ATLAS LINK BIOTECH
BECKMAN COULTER
BIOPHOR DIAGNOSTICS
BIO-RAD LABORATORIES
BIOSCAN SCREENING SYSTEMS
BRANAN MEDICAL CORP
CONCATENO, PLC
CONFIRM BIOSCIENCES
DEVON MEDICAL PRODUCTS
ELITECH GROUP
EXPRESS DIAGNOSTICS INTERNATIONAL INC.
HOFFMANN-LA ROCHE, LTD.
IDENTA CORP
LIFELOC TECHNOLOGIES
LIFESIGN
MAVAND SOLUTIONS
MEDTEST DX
MEDTOX DIAGNOSTICS
MICROGENICS
MOSSMAN ASSOCIATES
MP BIOMEDICALS
NANO-DITECH CORP.
ORASURE
ORTHO CLINICAL DIAGNOSTICS
POLYMED THERAPEUTICS
PRECHEK BIO
PRINCETON BIOMEDITECH
PSYCHEMEDICS
RANDOX LABORATORIES
REDWOOD TOXICOLOGY LABORATORY
ROCHE DIAGNOSTICS
SHIMADZU CORPORATION
SIEMENS HEALTHCARE DIAGNOSTICS
THERMO FISHER SCIENTIFIC
UCP BIOSCIENCES
Study Goals and Objectives
Reasons for Doing the Study
Intended Audience
Scope of Report
Methodology
Information Sources
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
Executive Summary
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Single- Vs. Multi-Parameter Test
DOA Screening
Confirmation Testing
Urine Tests
Other Testing Methods
Blood Testing
Oral Fluid Testing
Saliva Testing
Sweat Testing
Hair Testing
Testing Locations
Laboratory-Based DAT
Criminal Justice
Police
Prisons
Probation
Workplace Screening
Others
Military
Customs and Excise
Education
Point of Care DATS
Onsite Testing Vs Laboratory Testing
Sample Types for Laboratory Testing
Urine Testing
Hair Testing
Saliva/Oral Fluid Testing
Blood Testing
Sweat Testing
Eye Reflex
Detection Period
Fooling a Drug Test
Fooling Hair Testing
Fooling Saliva Testing
Sample Validity Tests
False Positives and False Negatives
False Positives
False Negatives
Drug Clearance and Testing Window
Testing Technologies
Immunoassays
Enzyme Immunoassay (EIA)
Enzyme-Linked Immunosorbent Assay (ELISA)
Enzyme Multiplied Immunoassay Technology (EMIT)
Fluorescence Polarization Immunoassay (FPIA)
Radioimmunoassay (RIA)
Chromatography
Gas Chromatography
High Performance Liquid Chromatography
Thin-Layer Chromatography
Mass Spectrometry
Capillary Electrophoresis
Hyphenated Mass Spectrometric/Chromatography
Gas Chromatography-Mass Spectrometry
Eye Reflex Measurements
CHAPTER 4 GOVERNMENT REGULATIONS: DRUG TRAFFICKING AND DRUG ABUSE TESTING
North America
Canada
Drug Free Workplace
Mexico
U.S.
Drug-Free Workplace
State Marijuana Legalization
U.S. Department of Transportation
Drug Testing in the Military
Drug Testing for Welfare Recipients and Public Assistance
History and Overview
Drug Testing for Individuals Convicted of Drug Felonies
2017 LEGISLATION
2016 LEGISLATION
Legislative Proposals
Legislative Enactments
2015 LEGISLATION
Legislative Proposals
Legislative Enactments
2014 LEGISLATION
Legislative Proposals
Legislative Enactments
2013 LEGISLATION
Legislative Proposals
Legislative Enactments
2012 LEGISLATION
South America
Bolivia
Brazil
Drug-Free Workplace
Colombia
Ecuador
Guyana
Paraguay
Peru
Central America and the Caribbean
Costa Rica
Cuba
El Salvador
Guatemala
Haiti
Jamaica
Nicaragua
Panama
Honduras
The Bahamas
The Netherlands Antilles
Trinidad and Tobago
Europe
Bosnia and Herzegovina
Denmark
France
Germany
Italy
Latvia
Norway
Romania
Sweden
Switzerland
The Netherlands
The United Kingdom
Asia-Pacific
Australia
Bangladesh
Bhutan
Cambodia
Hong Kong
India
The NDPS (Regulation of Controlled Substances) Order, 1993
Japan
Maldives
Myanmar
Nepal
New Zealand
Singapore
South Korea
Sri Lanka
Taiwan
Thailand
Vietnam
CHAPTER 5 OVERVIEW OF DRUG ABUSE TESTING
Drug Abuse Testing
International Drug Trafficking and Illicit Drug Use Trends by Drug Type
Amphetamine-Type Stimulants Market
Cannabis Market
Coca/Cocaine Market
Opium/Heroin Market
International Drug Trafficking and Illicit Drug Use Trends by Geographic Region
Africa
Central America and Caribbean
North America
South America
East and Southeast Asia
South Asia
West Asia
Europe
Oceania
U.S. DOA Statistics
National Household Survey on Drug Abuse: SAMHSA U.S.
CHAPTER 6 GLOBAL DRUGS OF ABUSE TESTING MARKET BY SAMPLE TYPE
DOA Testing Sales
Global Sales of DOA Testing by Urine
Global Sales of DOA Testing by Blood
Global Sales of DOA Testing by Oral Fluid
Global Sales of DOA Testing by Hair
Global Sales of DOA Testing by Sweat
Global Sales of DOA Testing by Other Sample Types
CHAPTER 7 GLOBAL INDUSTRY STRUCTURE
Regional Analysis
Total DOA Testing and Drug Monitoring Markets and Forecasts
Growth Trends-Laboratory-based and Onsite DOA Testing Markets
Laboratory-based DOA Testing Market and Forecast
Onsite DOA Testing Market and Forecast
Competitive Analysis
Key Market Players in the DOA Testing Markets and Their Products
Laboratory-based DOA Testing Market Segment
Onsite Testing Market Segment for DOA
Common DOA and Most Popular Devices Used for Testing Them
Companies in the Oral Fluid, Hair and Sweat Testing Segments for DOA
CHAPTER 8 PATENT ANALYSIS
CHAPTER 9 COMPANY PROFILES
1 STEP DETECT ASSOCIATES
ABBOTT DIAGNOSTICS
ACCUTECH
ACON LABORATORIES
AGILENT TECHNOLOGIES
ALERE
ALFA SCIENTIFIC
AMERICAN BIO MEDICA
ATLAS LINK BIOTECH
BECKMAN COULTER
BIOPHOR DIAGNOSTICS
BIO-RAD LABORATORIES
BIOSCAN SCREENING SYSTEMS
BRANAN MEDICAL CORP
CONCATENO, PLC
CONFIRM BIOSCIENCES
DEVON MEDICAL PRODUCTS
ELITECH GROUP
EXPRESS DIAGNOSTICS INTERNATIONAL INC.
HOFFMANN-LA ROCHE, LTD.
IDENTA CORP
LIFELOC TECHNOLOGIES
LIFESIGN
MAVAND SOLUTIONS
MEDTEST DX
MEDTOX DIAGNOSTICS
MICROGENICS
MOSSMAN ASSOCIATES
MP BIOMEDICALS
NANO-DITECH CORP.
ORASURE
ORTHO CLINICAL DIAGNOSTICS
POLYMED THERAPEUTICS
PRECHEK BIO
PRINCETON BIOMEDITECH
PSYCHEMEDICS
RANDOX LABORATORIES
REDWOOD TOXICOLOGY LABORATORY
ROCHE DIAGNOSTICS
SHIMADZU CORPORATION
SIEMENS HEALTHCARE DIAGNOSTICS
THERMO FISHER SCIENTIFIC
UCP BIOSCIENCES
LIST OF TABLES
Summary Table Global DOA Testing Market Forecast, by Test Type, Through 2022
Table 1 Advantages and Disadvantages of Point of Care Testing
Table 2 Major Advantages and Disadvantages of Onsite Testing
Table 3 Detection Periods for Various Types of Drug Testing
Table 4 Common Parameters Tested for Urine Specimen Validity
Table 5 Some of the Commercial/Common Adulterants Used in Fooling Urine Tests and Their Effects
Table 6 Urine Sample Validity Test Methods
Table 7 Cross Reactants That Can Lead to False Positives in DOA Testing
Table 8 Clearance Rates for Common DOA
Table 9 U.S. Drug Testing Legislations by State, 2017
Table 10 Selected State Marijuana Legalization, 2016
Table 11 Drug Testing Legislation by European Country
Table 12 Number of Illicit Drug Users Globally, 2015
Table 13 Number of Drug-Related Deaths, Mortality Rates per Million Persons Aged 15-64 Years and Ranking of Drugs as Primary Cause of Death (2014 or Latest Year Available), 2016
Table 14 Estimated Number of Drug-Related Deaths and Mortality Rates per Million Persons Aged 15-64 Years, 2014
Table 15 Annual Prevalence by Region, 2016
Table 16 U.S. DOA Seizures, 2014
Table 17 Annual Prevalence of Opioid Use as a Percentage of the Population Aged 15-64, 2015
Table 18 Annual Prevalence of Cocaine Use as a Percentage of the Population Aged 15-64, 2015
Table 19 Annual Prevalence of Cannabis Use as a Percentage of the Population Aged 15-64, 2015
Table 20 Annual Prevalence of ATS Use as a Percentage of the Population Aged 15-64, 2015
Table 21 Annual Prevalence of Ecstasy Use as a Percentage of the Population Aged 15-64, 2015
Table 22 Drug Abuse Statistics in the U.S. by Drug Type (12 Yrs and Older), 2014 and 2015
Table 23 U.S. Types of Illicit Drug Use in Lifetime, Past Year, and Past Month Among Persons Aged 18 or Older: Percentages, 2014 and 2015
Table 24 U.S. Illicit Drug Use in Lifetime, Past Year, and Past Month, by Detailed Age Category: Percentages, 2014 and 2015
Table 25 U.S. Marijuana Use in Lifetime, Past Year, and Past Month, by Detailed Age Category: Percentages, 2014 and 2015
Table 26 Global Sales Contribution for DOA Testing, by Sample Type, Through 2022
Table 27 Global Sales Forecast for DOA Testing, by Sample Type, Through 2022
Table 28 Global Sales Forecast for DOA Testing by Urine, Through 2022
Table 29 Global Sales Forecast for DOA Testing by Urine: Laboratory-based versus Onsite, through 2022
Table 30 Global Sales Forecast for DOA Testing, by Blood, Through 2022
Table 31 Global Sales Forecast for DOA Testing, by Oral Fluid, Through 2022
Table 32 Global Sales Forecast for DOA Testing by Oral Fluid: Laboratory-based versus Onsite, Through 2022
Table 33 Global Sales Forecast for DOA Testing, by Hair, Through 2022
Table 34 Global Sales Forecast for DOA Testing, by Sweat, Through 2022
Table 35 Global Sales Forecast for DOA Testing, by Other Sample Types, Through 2022
Table 36 Global DOA Testing Market Forecast, by Region, Through 2022
Table 37 DOA Testing Market Forecast for Laboratory-based DOA Testing, Through 2022
Table 38 DOA Testing Market Forecast for Onsite DOA Testing, Through 2022
Table 39 Most Notable Mergers and Acquisitions in the DOA Testing Markets, 2000-2016
Table 40 Major Companies and Their Products in the DOA Testing Market
Table 41 Companies Offering Laboratory-based DOA Testing Products
Table 42 Main Onsite DOA Testing Market Players and Their Products
Table 43 Common DOA and Popular Urine Drug Screening Products
Table 44 Key Market Players Offering DOA Testing Products on Oral Fluid, Hair and Sweat Sample Types
Table 45 Selected U.S. Patents Granted for DOA Testing, 2007-2017
Summary Table Global DOA Testing Market Forecast, by Test Type, Through 2022
Table 1 Advantages and Disadvantages of Point of Care Testing
Table 2 Major Advantages and Disadvantages of Onsite Testing
Table 3 Detection Periods for Various Types of Drug Testing
Table 4 Common Parameters Tested for Urine Specimen Validity
Table 5 Some of the Commercial/Common Adulterants Used in Fooling Urine Tests and Their Effects
Table 6 Urine Sample Validity Test Methods
Table 7 Cross Reactants That Can Lead to False Positives in DOA Testing
Table 8 Clearance Rates for Common DOA
Table 9 U.S. Drug Testing Legislations by State, 2017
Table 10 Selected State Marijuana Legalization, 2016
Table 11 Drug Testing Legislation by European Country
Table 12 Number of Illicit Drug Users Globally, 2015
Table 13 Number of Drug-Related Deaths, Mortality Rates per Million Persons Aged 15-64 Years and Ranking of Drugs as Primary Cause of Death (2014 or Latest Year Available), 2016
Table 14 Estimated Number of Drug-Related Deaths and Mortality Rates per Million Persons Aged 15-64 Years, 2014
Table 15 Annual Prevalence by Region, 2016
Table 16 U.S. DOA Seizures, 2014
Table 17 Annual Prevalence of Opioid Use as a Percentage of the Population Aged 15-64, 2015
Table 18 Annual Prevalence of Cocaine Use as a Percentage of the Population Aged 15-64, 2015
Table 19 Annual Prevalence of Cannabis Use as a Percentage of the Population Aged 15-64, 2015
Table 20 Annual Prevalence of ATS Use as a Percentage of the Population Aged 15-64, 2015
Table 21 Annual Prevalence of Ecstasy Use as a Percentage of the Population Aged 15-64, 2015
Table 22 Drug Abuse Statistics in the U.S. by Drug Type (12 Yrs and Older), 2014 and 2015
Table 23 U.S. Types of Illicit Drug Use in Lifetime, Past Year, and Past Month Among Persons Aged 18 or Older: Percentages, 2014 and 2015
Table 24 U.S. Illicit Drug Use in Lifetime, Past Year, and Past Month, by Detailed Age Category: Percentages, 2014 and 2015
Table 25 U.S. Marijuana Use in Lifetime, Past Year, and Past Month, by Detailed Age Category: Percentages, 2014 and 2015
Table 26 Global Sales Contribution for DOA Testing, by Sample Type, Through 2022
Table 27 Global Sales Forecast for DOA Testing, by Sample Type, Through 2022
Table 28 Global Sales Forecast for DOA Testing by Urine, Through 2022
Table 29 Global Sales Forecast for DOA Testing by Urine: Laboratory-based versus Onsite, through 2022
Table 30 Global Sales Forecast for DOA Testing, by Blood, Through 2022
Table 31 Global Sales Forecast for DOA Testing, by Oral Fluid, Through 2022
Table 32 Global Sales Forecast for DOA Testing by Oral Fluid: Laboratory-based versus Onsite, Through 2022
Table 33 Global Sales Forecast for DOA Testing, by Hair, Through 2022
Table 34 Global Sales Forecast for DOA Testing, by Sweat, Through 2022
Table 35 Global Sales Forecast for DOA Testing, by Other Sample Types, Through 2022
Table 36 Global DOA Testing Market Forecast, by Region, Through 2022
Table 37 DOA Testing Market Forecast for Laboratory-based DOA Testing, Through 2022
Table 38 DOA Testing Market Forecast for Onsite DOA Testing, Through 2022
Table 39 Most Notable Mergers and Acquisitions in the DOA Testing Markets, 2000-2016
Table 40 Major Companies and Their Products in the DOA Testing Market
Table 41 Companies Offering Laboratory-based DOA Testing Products
Table 42 Main Onsite DOA Testing Market Players and Their Products
Table 43 Common DOA and Popular Urine Drug Screening Products
Table 44 Key Market Players Offering DOA Testing Products on Oral Fluid, Hair and Sweat Sample Types
Table 45 Selected U.S. Patents Granted for DOA Testing, 2007-2017
LIST OF FIGURES
Summary Figure Global Drugs of Abuse Testing Market Forecast, by Test Matrix, 2016-2022
Figure 1 U.S. DOA Seizures, 2014
Figure 2 Global Sales Forecast for DOA Testing, by Sample Type, 2016-2022
Figure 3 Global Sales Forecast for Drugs of Abuse Testing by Urine, 2016-2022
Figure 4 Global Sales Forecast for Drugs of Abuse Testing by Urine: Laboratory-based versus Onsite, 2016-2022
Figure 5 Global Sales Forecast for Drugs of Abuse Testing, by Blood, 2016-2022
Figure 6 Global Sales Forecast for Drugs of Abuse Testing, by Oral Fluid, 2016-2022
Figure 7 Global Sales Forecast for Drugs of Abuse Testing, by Oral Fluid: Laboratory-based versus Onsite, 2016-2022
Figure 8 Global Sales Forecast for Drugs of Abuse Testing, by Hair, 2016-2022
Figure 9 Global Sales Forecast for Drugs of Abuse Testing by Sweat, 2016-2022
Figure 10 Global Sales Forecast for DOA Testing, by Other Sample Types, 2016-2022
Figure 11 Drugs of Abuse Testing Markets, by Geographic Region, 2017
Summary Figure Global Drugs of Abuse Testing Market Forecast, by Test Matrix, 2016-2022
Figure 1 U.S. DOA Seizures, 2014
Figure 2 Global Sales Forecast for DOA Testing, by Sample Type, 2016-2022
Figure 3 Global Sales Forecast for Drugs of Abuse Testing by Urine, 2016-2022
Figure 4 Global Sales Forecast for Drugs of Abuse Testing by Urine: Laboratory-based versus Onsite, 2016-2022
Figure 5 Global Sales Forecast for Drugs of Abuse Testing, by Blood, 2016-2022
Figure 6 Global Sales Forecast for Drugs of Abuse Testing, by Oral Fluid, 2016-2022
Figure 7 Global Sales Forecast for Drugs of Abuse Testing, by Oral Fluid: Laboratory-based versus Onsite, 2016-2022
Figure 8 Global Sales Forecast for Drugs of Abuse Testing, by Hair, 2016-2022
Figure 9 Global Sales Forecast for Drugs of Abuse Testing by Sweat, 2016-2022
Figure 10 Global Sales Forecast for DOA Testing, by Other Sample Types, 2016-2022
Figure 11 Drugs of Abuse Testing Markets, by Geographic Region, 2017
